At the Duke Cancer Institute, a researcher performed a study to know how effective umbilical cord blood would be while dealing with blood cancer. For patients with blood cancer, a bone marrow transplant is needed. Cord blood contains a large number of stem cells within it. It’s sufficient when doing a transplant in children. But the stem cells are not up to the requirement of adults. To fulfill the requirements of adult transplantation process, umbilical cord blood is treated for 3 weeks outside the patient where it is cultivated with stem cells. In this way, it is made fit for adults.
The findings from phase I/II study of biological treatment, NiCord at 11 clinical trial sites claim that blood cells from umbilical cord prove very beneficial while bone marrow transplant so these are cultures outside the body.
Horwitz said that Gamida Cell now aims to seek FDA approval for the product and for this NiCord phase III trial is underway. Clinical trials were conducted in which Horwitz and colleagues analyzed the results of 36 victims who were given stem cells after expansion. Researchers found successful engraftment of product in 94%patients receiving blood after expansion whereas 2 patients couldn’t tolerate them.
Patients having expanded blood could face infections more strongly. The median time for neutrophil recovery and platelet recovery was also shorter than as compared to such patients who hadn’t received cultured blood.
Patients who received cord blood alone recovered in 21 days for neutrophils whereas those with expanded blood recovered this deficiency in 11.5 days. 34 days for NiCord group and 46 days for cord blood were the number of people in groups in which platelet recovery was seen.
According to Horwitz “when blood counts are low, patients are more vulnerable to infections.”
Reducing neutrophil recovery time means increasing the capacity of the body to fight with diseases.